Angiology

Recently Published Research on Stendra®(avanafil) for Endothelial Function in Men with Erectile Dysfunction to Initiate Petros Pharmaceuticals' Plans for Expanded Labeling

Retrieved on: 
Thursday, March 18, 2021
Medical specialties, Diabetes, Human sexuality, Angiology, Endothelium, Endothelial dysfunction, Comorbidity, Clinical medicine, Erectile dysfunction

Petros plans on using this research to initiate discussions with the FDA on expanding the label for Stendra for the indication to potentially include improvement in endothelial function.

Key Points: 
  • Petros plans on using this research to initiate discussions with the FDA on expanding the label for Stendra for the indication to potentially include improvement in endothelial function.
  • Like diabetes, hypertension, and dyslipidemia, endothelial dysfunction is also a common co-morbidity of erectile dysfunction.
  • The study authors noted that, "limitations of this study were the small sample size and the short period for follow up.
  • Study subjects also had comorbidities, including diabetes, hypertension and dyslipidemia, which are associated with a reduction in endothelial function.

Wet Age-Related Macular Degeneration Market to Flourish with a 4.5% CAGR and has a Promising Outlook with Emerging Therapies, Estimates DelveInsight

Retrieved on: 
Wednesday, March 17, 2021
Ophthalmology, Clinical medicine, Medicine, Angiology, Anti–vascular endothelial growth factor therapy, Macular degeneration, Monoclonal antibodies, Maculopathy, Rinucumab

The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • Anti-VEGF medications have been revolutionary for treating neovascular, or exudative, age-related macular degeneration, but unmet needs continue.
  • Also, it has been observed that Wet Age-Related Macular Degeneration is more prominent in females as compared to males.
  • The Wet Age-Related Macular Degeneration Market Report provides historical as well as forecasted epidemiological analysis segmented into:

Wet Age-Related Macular Degeneration Market to Flourish with a 4.5% CAGR and has a Promising Outlook with Emerging Therapies, Estimates DelveInsight

Retrieved on: 
Wednesday, March 17, 2021
Ophthalmology, Clinical medicine, Medicine, Angiology, Anti–vascular endothelial growth factor therapy, Macular degeneration, Monoclonal antibodies, Maculopathy, Rinucumab

The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • Anti-VEGF medications have been revolutionary for treating neovascular, or exudative, age-related macular degeneration, but unmet needs continue.
  • Also, it has been observed that Wet Age-Related Macular Degeneration is more prominent in females as compared to males.
  • The Wet Age-Related Macular Degeneration Market Report provides historical as well as forecasted epidemiological analysis segmented into:

OXURION to Participate in Upcoming Investor Meetings

Retrieved on: 
Monday, March 8, 2021
Branches of biology, Clinical medicine, Medicine, Angiology, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor, Euronext

THR-149 has shown positive topline Phase 1 results for the treatment of DME.

Key Points: 
  • THR-149 has shown positive topline Phase 1 results for the treatment of DME.
  • The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.

Healthcare Leader, Ali Bauerlein, Joins Koya Medical's Board of Directors

Retrieved on: 
Thursday, March 4, 2021
Angiology, Circulatory system, Medical specialties, Lymphedema, Vein

OAKLAND, Calif., March 4, 2021 /PRNewswire/ --Koya Medical ( www.koyamedical.com ), a healthcare company focused on developing breakthrough treatments for lymphedema and venous disorders, today announced the appointment of Ali Bauerlein to its Board of Directors.

Key Points: 
  • OAKLAND, Calif., March 4, 2021 /PRNewswire/ --Koya Medical ( www.koyamedical.com ), a healthcare company focused on developing breakthrough treatments for lymphedema and venous disorders, today announced the appointment of Ali Bauerlein to its Board of Directors.
  • "I am honored to help the Koya Medical team in their mission to improve the lives of patients suffering from chronic lymphedema and venous diseases," said Ms. Bauerlein.
  • "Ali is an experienced executive with a strong history of building shareholder value in the healthcare domain," said Josh Baltzell, Chairman/Board Director at Koya Medical.
  • Koya Medical, founded in 2018, is a privately held healthcare company with a mission to treatlymphedema and venous diseases through innovative patient-centric platforms.

PureTech Announces Publication of Glyph™ Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release

Retrieved on: 
Thursday, February 25, 2021
Health, Other Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Philosophy, Academic disciplines, Branches of philosophy, Angiology, Animal anatomy, Lymphatic system, Proof of concept, Proof

Results provide further preclinical proof-of-concept for PureTechs Glyph platform technology, which is designed to traffic small molecule therapeutics directly into the lymphatic system via oral administration.

Key Points: 
  • Results provide further preclinical proof-of-concept for PureTechs Glyph platform technology, which is designed to traffic small molecule therapeutics directly into the lymphatic system via oral administration.
  • View the full release here: https://www.businesswire.com/news/home/20210225005700/en/
    PureTech announced the publication of a paper in the Journal of Controlled Release.
  • Results provide further preclinical proof-of-concept for PureTechs lymphatic targeting technology platform Glyph, which is designed to traffic small molecule therapeutics directly into the lymphatic system via oral administration.
  • This in vivo proof of concept is an excellent foundation for advancing drug development that leverages the Glyph platform.

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

Retrieved on: 
Thursday, February 25, 2021
Medical specialties, Branches of biology, Clinical medicine, Angiology, Vascular endothelial growth factor, Uveitis, Macular degeneration, Retinal vasculitis, Angiogenesis, Retina

The paper, entitled "Immune-Mediated Retinal Vasculitis in Posterior Uveitis and Experimental Models: The Leukotriene (LT)B4-VEGF Axis," highlights the importance of the LTB4-VEGF axis in the development of sight-threatening retinal inflammation.

Key Points: 
  • The paper, entitled "Immune-Mediated Retinal Vasculitis in Posterior Uveitis and Experimental Models: The Leukotriene (LT)B4-VEGF Axis," highlights the importance of the LTB4-VEGF axis in the development of sight-threatening retinal inflammation.
  • In addition, PAS-nomacopan was significantly more effective in reducing retinal inflammation than the anti-VEGF antibody.
  • In this model, PAS-nomacopan injected once during the 16-day treatment period was equivalent to Eyelea in reducing neo-vascularisation.
  • C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.

InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

Retrieved on: 
Wednesday, February 24, 2021
Medical specialties, Angiology, Cardiovascular system, Neurosurgery, Vascular surgery, Vascular diseases, Carotid stenting, Carotid artery stenosis, Stroke, Carotid artery, Carotid endarterectomy

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.

Key Points: 
  • TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.
  • HCC is ideally suited to manage this trial having supported clinical trial operations for a variety of products and indications, including with multiple carotid intervention procedures, stated Marvin Slosman, InspireMDs CEO.
  • This will be the first U.S.-based study of CGuard and our opportunity to demonstrate its potential for the prevention of stroke caused by carotid artery disease in patients in the United States.
  • We look forward to working with InspireMD on this pivotal trial of the CGuard System to help establish a new standard of care for the management of carotid artery disease and stroke prevention.

Abiomed to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Health, Cardiology, Medical devices, Exercise physiology, Branches of biology, Anatomy, Circulatory system, Abiomed, Forward-looking statement, Angiology, Danvers, Massachusetts, Heart, Hemodynamics

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.

Key Points: 
  • Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.
  • Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
  • All statements, other than statements of historical facts, may be forward-looking statements.
  • Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program

Retrieved on: 
Tuesday, February 16, 2021
Angiology, Aromatic compounds, Chemical compounds, Medical specialties, Medical terminology, Neovascularization, Bascom Palmer Eye Institute, Angiogenesis, Fluorescein

delivered a presentation entitled, Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Bascom Palmer Eye Institute on February 12 & 13, 2021.

Key Points: 
  • delivered a presentation entitled, Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Bascom Palmer Eye Institute on February 12 & 13, 2021.
  • This compartmentalized delivery to affected posterior tissues may minimize treatment related adverse events, such as vitreous floaters and corneal and anterior segment exposure.
  • Preclinical results from Clearside and independent investigators have shown pharmacodynamic effects with reduced growth of experimental neovascularization and decreased fluorescein leakage.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.